Chongqing Zhifei Biological Products Balance Sheet Health
Financial Health criteria checks 6/6
Chongqing Zhifei Biological Products has a total shareholder equity of CN¥32.7B and total debt of CN¥5.0B, which brings its debt-to-equity ratio to 15.3%. Its total assets and total liabilities are CN¥53.6B and CN¥20.9B respectively. Chongqing Zhifei Biological Products's EBIT is CN¥8.5B making its interest coverage ratio -34925.2. It has cash and short-term investments of CN¥3.0B.
Key information
15.3%
Debt to equity ratio
CN¥5.01b
Debt
Interest coverage ratio | -34925.2x |
Cash | CN¥2.97b |
Equity | CN¥32.66b |
Total liabilities | CN¥20.91b |
Total assets | CN¥53.57b |
Recent financial health updates
We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt
Jul 26Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?
Mar 26Recent updates
We Think Chongqing Zhifei Biological Products (SZSE:300122) Can Stay On Top Of Its Debt
Jul 26Why Investors Shouldn't Be Surprised By Chongqing Zhifei Biological Products Co., Ltd.'s (SZSE:300122) Low P/E
May 21Earnings Miss: Chongqing Zhifei Biological Products Co., Ltd. Missed EPS By 35% And Analysts Are Revising Their Forecasts
Apr 26Is Chongqing Zhifei Biological Products (SZSE:300122) A Risky Investment?
Mar 26Financial Position Analysis
Short Term Liabilities: 300122's short term assets (CN¥45.7B) exceed its short term liabilities (CN¥20.2B).
Long Term Liabilities: 300122's short term assets (CN¥45.7B) exceed its long term liabilities (CN¥693.1M).
Debt to Equity History and Analysis
Debt Level: 300122's net debt to equity ratio (6.3%) is considered satisfactory.
Reducing Debt: 300122's debt to equity ratio has reduced from 31.7% to 15.3% over the past 5 years.
Debt Coverage: 300122's debt is well covered by operating cash flow (114.9%).
Interest Coverage: 300122 earns more interest than it pays, so coverage of interest payments is not a concern.